Novo Nordisk’s $570 billion valuation is more than Denmark’s GDP—but PM isn’t worried about a ‘Nokia risk’
But Danish prime minister Mette Frederiksen isn't worried about a 'Nokia risk' from pharma giant.
Ozempic and Wegovy Sales Will Soon Pay for $68 Billion of Novo R&D
Ozempic and Wegovy are making so much money for Novo Nordisk A/S that their cumulative sales will soon surpass the ...
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
Novo Nordisk's New Weight Loss Drug Shows Ominous Psychiatric Side Effects
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...
Questions over Novo Nordisk $1bn weight loss drug after Phase IIa trial
Novo Nordisk acquired monlunabant in a $1bn deal last year, but the Phase IIa trial raises questions over the efficacy and ...
Novo Nordisk shares drop nearly 5% on disappointing obesity pill data
By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...
devdiscourse1d
Key Developments in Health: Novo Nordisk's Wegovy, Zevra's Breakthrough, and More
This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...
Novo Nordisk's experimental weight loss pill has some concerning side effects
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise ...